Psilocybin is best known for its metabolic effects on perception, mood, and consciousness. In recent years, it has also gained attention in psychiatry for its potential to treat depression, anxiety, and existential distress. A new preclinical study now suggests that low-dose psilocybin may influence something very different: metabolic health. Importantly, these benefits appear to occur without producing psychedelic effects.
The findings come from a study published in Pharmacological Research, which explored whether chronic, non-psychedelic doses of psilocybin could reduce obesity-related metabolic problems in mice. While the research is still early and limited to animals, it opens an unexpected new line of investigation into how psychedelic compounds may act outside the brain.
Understanding Low-Dose Psilocybin Metabolic Effects and Health
Psilocybin is converted in the body to psilocin, a compound that interacts with serotonin receptors. Most psychedelic effects are linked to activation of the 5-HT2A receptor in the brain. However, serotonin receptors are also found throughout the body, including in the liver, gut, muscle, and fat tissue. This study focused on whether targeting these peripheral receptors could influence metabolism.
The researchers used a very low dose of psilocybin designed to avoid behavioral or cognitive changes. The goal was not to study altered states of consciousness, but rather to examine potential physiological effects relevant to obesity, type 2 diabetes, and fatty liver disease.
How the Study Was Designed for Metabolic Effects
Male C57BL/6J mice were fed a high-fat, high-fructose diet known to reliably induce obesity, insulin resistance, and liver steatosis. After five weeks on this diet, the mice were split into two groups. One group received daily oral doses of psilocybin at 0.05 mg per kilogram of body weight for 12 weeks. The control group received water.
At the end of the study, the researchers assessed body weight, glucose regulation, liver health, muscle function, and behavioral outcomes. They also analyzed metabolic pathways in liver tissue to better understand how psilocybin might be exerting its effects.
Key Findings From the Mouse Model
Compared to control mice, those receiving low-dose psilocybin gained less weight despite consuming the same obesogenic diet. They showed lower blood glucose levels, improved insulin sensitivity, and significantly reduced fatty liver changes. Markers of lipid and carbohydrate metabolism in the liver were close to normal in treated mice.
Notably, the researchers did not observe changes in behavior or signs of central nervous system activation. This suggests that the metabolic improvements were not driven by appetite suppression, altered activity, or psychedelic effects.
The study also found improvements in muscle strength and function. These changes may be linked to restored leptin sensitivity. Leptin is a hormone that helps regulate energy balance and is often dysregulated in obesity.
Why Serotonin Receptors Outside the Brain Matter
Further analysis pointed to activation of the 5-HT2B serotonin receptor in the liver as a key mechanism. This pathway appears to be distinct from the brain-based mechanisms responsible for psychedelic experiences. By acting on peripheral serotonin signaling, low-dose psilocybin may influence how the liver processes fats and sugars.
This finding is important because it suggests that psychedelic compounds may have therapeutic potential beyond mental health, especially when used at doses that do not alter perception or cognition.
What This Means and What Comes Next
While these results are promising, it is essential to emphasize that this was an animal study. Mice and humans share many biological pathways, but results do not always translate directly to clinical benefit. Human trials would be needed to determine safety, dosing, and real-world effectiveness.
Still, this research expands how clinicians and researchers think about psilocybin. It suggests that low-dose psilocybin metabolic health effects may one day become part of broader conversations about innovative treatments for obesity, type 2 diabetes, and fatty liver disease.
Citations
Hedrih V. Low-dose psilocybin reduces weight gain and hyperglycemia in mice fed an obesogenic diet. PsyPost. February 16, 2026. https://www.psypost.org/low-dose-psilocybin-reduces-weight-gain-and-hyperglycemia-in-mice-fed-obesogenic-diet/
Nichols DE. Psychedelics. Pharmacological Reviews. 2016. https://doi.org/10.1124/pr.115.011478